MiraKind’s research relies on patients to help understand how unique personal genetics play a role in disease risk and how they can be used to guide personalized prevention approaches.

Our research investigates a recently discovered class of biomarkers based on a new understanding of genetics and DNA. The studied genetic variants are unlike any other inherited genetic markers, because of where they are found in the DNA, and most importantly, how they work and respond to life stress.20

Patients who have these variants respond differently to external stresses which can lead to cancer and disease development. We believe these genetic variants have the ability to both predict disease as well as identify strategies to prevent disease, and thus they show incredible potential for developing prevention and treatment strategies.1-7

heart with hands icon

Together, we can learn ways to take important steps towards both disease prevention and improving treatment outcomes.

If you are a women over 40 years old, you can help by enrolling in a study.

You can start the process by taking a 10-15 minute survey. Please visit our enroll in a study page here to learn more and access the survey.

Our first discovered biomarker, the inherited KRAS-variant, is:

  • An inherited, genetic marker that has significant implications for women’s health
  • A predictor of breast3, ovarian2 and lung cancer1
  • A biomarker that identifies women who can be protected from cancer by maintaining estrogen levels7
  • Identifies patients who will respond uniquely to cancer treatment22,23

Current research questions include:

  • What is the role of hormone replacement therapy in breast cancer risk? Who, beyond women with the KRAS-variant, are at risk, and who is protected?
  • What is the impact of anti-estrogens for women with the KRAS-variant and other variants like it?
  • How can cancer survivors who are positive for the KRAS-variant protect themselves from secondary cancers?
arrow up to top